Nautilus Biotechnology (NASDAQ:NAUT – Get Rating) is one of 42 publicly-traded companies in the “Analytical instruments” industry, but how does it compare to its peers? We will compare Nautilus Biotechnology to similar companies based on the strength of its analyst recommendations, dividends, profitability, risk, institutional ownership, earnings and valuation.
This table compares Nautilus Biotechnology and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Nautilus Biotechnology Competitors||-187.73%||3.44%||-10.22%|
This is a summary of recent recommendations for Nautilus Biotechnology and its peers, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Nautilus Biotechnology Competitors||318||1316||1817||57||2.46|
Nautilus Biotechnology currently has a consensus price target of $8.67, indicating a potential upside of 151.21%. As a group, “Analytical instruments” companies have a potential upside of 40.32%. Given Nautilus Biotechnology’s stronger consensus rating and higher probable upside, equities analysts clearly believe Nautilus Biotechnology is more favorable than its peers.
Valuation & Earnings
This table compares Nautilus Biotechnology and its peers top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Nautilus Biotechnology||N/A||-$50.31 million||-6.05|
|Nautilus Biotechnology Competitors||$1.19 billion||$356.47 million||-7.82|
Nautilus Biotechnology’s peers have higher revenue and earnings than Nautilus Biotechnology. Nautilus Biotechnology is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.
Insider and Institutional Ownership
47.9% of Nautilus Biotechnology shares are owned by institutional investors. Comparatively, 61.3% of shares of all “Analytical instruments” companies are owned by institutional investors. 13.3% of shares of all “Analytical instruments” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Nautilus Biotechnology peers beat Nautilus Biotechnology on 8 of the 12 factors compared.
Nautilus Biotechnology Company Profile (Get Rating)
Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. It develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. The company was founded in 2016 and is headquartered in Seattle, Washington.
Receive News & Ratings for Nautilus Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nautilus Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.